Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment

Introduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamin...

Full description

Bibliographic Details
Main Authors: Mary Lynch, Dwight Moulin, Jordy Perez
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Canadian Journal of Pain
Subjects:
Online Access:http://dx.doi.org/10.1080/24740527.2019.1660575
id doaj-2f8c962341f3427a89317daf1084483f
record_format Article
spelling doaj-2f8c962341f3427a89317daf1084483f2021-01-04T18:52:24ZengTaylor & Francis GroupCanadian Journal of Pain2474-05272019-01-013118018910.1080/24740527.2019.16605751660575Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitmentMary Lynch0Dwight Moulin1Jordy Perez2Dalhousie UniversityWestern UniversityAlan Edwards Pain Management UnitIntroduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamines. It was hypothesized that with these three mechanisms of action methadone might be a good option for the treatment of neuropathic pain. Methods: This was a double-blind randomized controlled trial comparing methadone to controlled-release morphine. The primary objective was to determine whether methadone is clinically inferior versus noninferior to morphine as an analgesic. Results: We attempted recruitment at three academic pain centers over a 3-year period. In the end only 14 participants were able to be recruited; 5 withdrew and only 9 completed the trial. This study was underpowered. All participants showed a mean reduction in pain intensity according to the Numeric Rating Scale for Pain Intensity (morphine 5.86 to 4.38, methadone 6.11 to 4.5) and reported pain relief compared to pretreatment, but the sample size was too small for statistical analysis. Discussion: Reasons for challenges in recruitment included tight inclusion and exclusion criteria and high participant burden. In addition, there was significant heterogeneity of patients between the three sites, leading to differences in reasons for exclusion. This included seemingly disparate reasons at the different sites, including few participants who were methadone naïve vs. avoidance or fear of opioids. In the end, we were unable to answer the question of the study.http://dx.doi.org/10.1080/24740527.2019.1660575neuropathic painopioidsmethadonestudy recruitment
collection DOAJ
language English
format Article
sources DOAJ
author Mary Lynch
Dwight Moulin
Jordy Perez
spellingShingle Mary Lynch
Dwight Moulin
Jordy Perez
Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
Canadian Journal of Pain
neuropathic pain
opioids
methadone
study recruitment
author_facet Mary Lynch
Dwight Moulin
Jordy Perez
author_sort Mary Lynch
title Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
title_short Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
title_full Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
title_fullStr Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
title_full_unstemmed Methadone vs. morphine SR for treatment of neuropathic pain: A randomized controlled trial and the challenges in recruitment
title_sort methadone vs. morphine sr for treatment of neuropathic pain: a randomized controlled trial and the challenges in recruitment
publisher Taylor & Francis Group
series Canadian Journal of Pain
issn 2474-0527
publishDate 2019-01-01
description Introduction: Accumulating evidence has identified a number of advantages for methadone over other opioids for the treatment of chronic pain including: agonist action at both μ and δ opioid receptors, N-methyl-d-aspartate (NMDA) antagonist activity and the ability to inhibit the reuptake of monoamines. It was hypothesized that with these three mechanisms of action methadone might be a good option for the treatment of neuropathic pain. Methods: This was a double-blind randomized controlled trial comparing methadone to controlled-release morphine. The primary objective was to determine whether methadone is clinically inferior versus noninferior to morphine as an analgesic. Results: We attempted recruitment at three academic pain centers over a 3-year period. In the end only 14 participants were able to be recruited; 5 withdrew and only 9 completed the trial. This study was underpowered. All participants showed a mean reduction in pain intensity according to the Numeric Rating Scale for Pain Intensity (morphine 5.86 to 4.38, methadone 6.11 to 4.5) and reported pain relief compared to pretreatment, but the sample size was too small for statistical analysis. Discussion: Reasons for challenges in recruitment included tight inclusion and exclusion criteria and high participant burden. In addition, there was significant heterogeneity of patients between the three sites, leading to differences in reasons for exclusion. This included seemingly disparate reasons at the different sites, including few participants who were methadone naïve vs. avoidance or fear of opioids. In the end, we were unable to answer the question of the study.
topic neuropathic pain
opioids
methadone
study recruitment
url http://dx.doi.org/10.1080/24740527.2019.1660575
work_keys_str_mv AT marylynch methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment
AT dwightmoulin methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment
AT jordyperez methadonevsmorphinesrfortreatmentofneuropathicpainarandomizedcontrolledtrialandthechallengesinrecruitment
_version_ 1724348967694630912